Search

everythinglearnresearchcommunity

for

Search:↓

IFNγ-primed MSC secretomes can improve joint health by reducing inflammation and supporting tissue repair.

CXCL12+ fibroblasts help recruit neutrophils to fight skin infections.

The immune processes causing VKH and vitiligo are similar in dogs and humans.

Reprogramming macrophages to resolve inflammation can help reduce severe COVID-19 complications.

Nanomedicine-based immunotherapy shows promise in improving tissue repair and regeneration.

Different types of cell death affect skin health and inflammation, and understanding them could improve treatments for skin diseases.

Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.

Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.

RORA plays a key role in controlling seasonal hair molting by affecting hair follicle cell activity.

Asthma may increase the risk of alopecia areata.

Notch signaling disruptions can cause various skin diseases.

Manipulating cell cleanup processes could help treat hair loss.

Mesenchymal stem cells could help treat radiation-induced bladder damage but more research is needed to overcome current limitations.

Alopecia areata involves complex immune dysregulation, mainly driven by Th1 activity, suggesting broader treatment strategies.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Oleoylethanolamide (OEA) safely boosts fat production in skin cells and may help treat dry skin and reduce inflammation.

Claudin-1 and Claudin-3 are crucial for keeping hair follicle structure and preventing a type of hair loss called telogen effluvium.

The role of γδT-cells in causing alopecia areata remains unclear.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Apremilast did not work for treating severe alopecia areata.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

ILC1 cells contribute to hair loss in alopecia areata.

Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.

New treatments offer hope for better managing hidradenitis suppurativa.

Higher IL-17A levels indicate more severe alopecia areata.

Inflammasome proteins can indicate the severity and treatment response of various diseases and injuries.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Different scaffold patterns improve wound healing and immune response in mouse skin, with aligned patterns being particularly effective.